Results 151 to 160 of about 1,884,582 (342)
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez+5 more
wiley +1 more source
While rapid development and roll out of COVID-19 vaccines is necessary in a pandemic, the process limits the ability of clinical trials to assess longer-term vaccine efficacy. We leveraged COVID-19 surveillance data in the U.S.
Mia Moore+10 more
doaj
A randomized controlled trial of hemodilution therapy in acute ischemic stroke. [PDF]
T Strand+5 more
openalex +1 more source
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima+6 more
wiley +1 more source
Xuan Yin,1,* Wei Li,1,2,* Huangan Wu,3,* Bo Dong,1 Jie Ma,1 Shanshan Li,1 Lixing Lao,4,5 Shifen Xu1 1Department of Acupuncture and Moxibustion, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese ...
Yin X+7 more
doaj
A controlled, prospective, randomized trial evaluating the metabolic effects of enteral and parenteral nutrition in the cancer patient [PDF]
Michael Burt+2 more
openalex +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
Treatment of Men with Idiopathic Oligozoospermic Infertility Using the Aromatase Inhibitor, Testolactone Results of a Double‐Blinded, Randomized, Placebo‐Controlled Trial with Crossover [PDF]
Richard V. Clark, Richard J. Sherins
openalex +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source